Drawbacks of Artificial Intelligence and Their Potential Solutions in the Healthcare Sector

被引:148
作者
Bangul khan
Hajira Fatima
Ayatullah Qureshi
Sanjay Kumar
Abdul Hanan
Jawad Hussain
Saad Abdullah
机构
[1] Hong Kong Centre for Cerebro-Caradiovasular Health Engineering (COCHE), Shatin
[2] Riphah International University, Lahore
[3] Mehran University of Engineering and Technology, Jamshoro
[4] NED University, Karachi
[5] Mälardalen University, Västerås
来源
Biomedical Materials & Devices | 2023年 / 1卷 / 2期
关键词
Artificial intelligence; Clinical practices; Health sector; IoT; Machine learning;
D O I
10.1007/s44174-023-00063-2
中图分类号
学科分类号
摘要
Artificial intelligence (AI) has the potential to make substantial progress toward the goal of making healthcare more personalized, predictive, preventative, and interactive. We believe AI will continue its present path and ultimately become a mature and effective tool for the healthcare sector. Besides this AI-based systems raise concerns regarding data security and privacy. Because health records are important and vulnerable, hackers often target them during data breaches. The absence of standard guidelines for the moral use of AI and ML in healthcare has only served to worsen the situation. There is debate about how far artificial intelligence (AI) may be utilized ethically in healthcare settings since there are no universal guidelines for its use. Therefore, maintaining the confidentiality of medical records is crucial. This study enlightens the possible drawbacks of AI in the implementation of healthcare sector and their solutions to overcome these situations. Graphical Abstract: (Figure presented.) © The Author(s), under exclusive licence to Springer Science+Business Media, LLC 2023.
引用
收藏
页码:731 / 738
页数:7
相关论文
共 60 条
  • [1] Chan H.C.S., Shan H., Dahoun T., Vogel H., Yuan S., Advancing drug discovery via artificial intelligence, Trends Pharmacol. Sci, 40, 8, pp. 592-604, (2019)
  • [2] Cruciger O., Schildhauer T.A., Meindl R.C., Tegenthoff M., Schwenkreis P., Citak M., Aach M., Impact of locomotion training with a neurologic controlled hybrid assistive limb (HAL) exoskeleton on neuropathic pain and health related quality of life (HRQoL) in chronic SCI: a case study, Disabil. Rehabil. Assist. Technol, 11, 6, pp. 529-534, (2016)
  • [3] Diaz O., Dalton J.A.R., Giraldo J., Artificial intelligence: a novel approach for drug discovery, Trends Pharmacol. Sci, 40, 8, pp. 550-551, (2019)
  • [4] Habermann J., Psychological Impacts of COVID-19 and Preventive Strategies: A Review, (2021)
  • [5] Harrer S., Shah P., Antony B., Hu J., Artificial intelligence for clinical trial design, Trends Pharmacol. Sci, 40, 8, pp. 577-591, (2019)
  • [6] Holzinger A., Biemann C., Pattichis C.S., Kell D.B., What Do We Need to Build Explainable AI Systems for the Medical Domain, (2017)
  • [7] Hummel P., Braun M., Just data? Solidarity and justice in data-driven medicine, Life Sci., Soc. Policy, 16, 1, pp. 1-18, (2020)
  • [8] Schmidt-Erfurth U., Bogunovic H., Sadeghipour A., Et al., Machine learning to analyze the prognostic value of current imaging biomarkers in neovascular age-related macular degeneration, Opthamol. Retina, 2, pp. 24-30, (2018)
  • [9] Lee S.I., Celik S., Logsdon B.A., Et al., A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia, Nat. Commun, 9, (2018)
  • [10] Sordo M., Introduction to neural networks in healthcare, Openclin., (2002)